Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail
At this stage of the game, Novartis CEO Vas Narasimhan may be wishing he’d never even heard of canakinumab.
After steering the drug straight to …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
